INGELHEIM, Germany - Monday, June 24th 2013 [ME NewsWire]
Data show Pradaxa® is as effective as the standard of care while offering safety advantages in the treatment of acute and the prevention of recurrent DVT and PE1,2,3
Pradaxa® is already approved for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation and for the primary prevention of venous thromboembolic events in patients undergoing elective total hip replacement or total knee replacement surgery4
In-market experience with Pradaxa® already spans over 1.6 million patient-years in all currently licensed indications in over 100 countries worldwide5
(BUSINESS WIRE)-- For media outside of the U.S., the UK & Canada only
Boehringer Ingelheim today announced the submission of an application to the European Medicines Agency (EMA) for use of Pradaxa® (dabigatran etexilate) for the treatment
...
Read more »